BLSM BlossomHill Therapeutics, Inc. - Common Stock
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Sep 18, 2026BLSM Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
BLSM Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | BLSM | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | -0.3 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | BLSM | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 5.4 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-8.75 | $-1.03 | -746.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
We don't have SEC filings for this ticker yet.
Income Statement
| Metric | Trend | Q2 2026 |
|---|---|---|
| R&D Expense | $21M | |
| SG&A Expense | $3M | |
| Operating Expenses | $25M | |
| Operating Income | $-25M | |
| Other Non-op | $912.0K | |
| Net Income | $-24M | |
| EPS (Basic) | $-8.75 | |
| EPS (Diluted) | $-8.75 | |
| Shares (Basic) | 2,713,696 | |
| Shares (Diluted) | 2,713,696 | |
| EBITDA | $-25M |
Balance Sheet
| Metric | Trend | Q2 2026 |
|---|---|---|
| Cash & Equivalents | $95M | |
| Prepaid Expense | $6M | |
| Current Assets | $101M | |
| PP&E (Net) | $1M | |
| Other Non-current Assets | $2M | |
| Total Assets | $124M | |
| Accounts Payable | $4M | |
| Accrued Liabilities | $4M | |
| Current Liabilities | $19M | |
| Capital Leases | $22M | |
| Other Non-current Liabilities | $1M | |
| Total Liabilities | $42M | |
| Common Stock | $1.0K | |
| Paid-in Capital | $5M | |
| Retained Earnings | $-180M | |
| Stockholders' Equity | $-175M | |
| Liabilities + Equity | $124M | |
| Shares Outstanding | 2,548,659 |
Profitability
| Metric | Trend | Q2 2026 |
|---|---|---|
| ROA | -38.3% | |
| ROE | 27.2% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 |
|---|---|---|
| Current Ratio | 5.4 | |
| Quick Ratio | 5.1 |
Per Share
| Metric | Trend | Q2 2026 |
|---|---|---|
| Book Value / Share | $-68.58 | |
| Cash / Share | $37.42 |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC | Aug. 18, 2026 | 8.90% | Initial filing | · | SEC |
| Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare Fund V, LP, Cormorant Private Healthcare GP V, LLC, Cormorant Private Healthcare Fund VI, LP, Cormorant Private Healthcare GP VI, LLC, Cormorant Asset Management, LP, Chen Bihua | Aug. 13, 2026 | 11.80% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 8 insiders · 5 officers · 4 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jingrong Jean Cui | President and CEO | Aug. 10, 2026 C | 124,779 | 0 | 0 | $0 |
| Jason A Keyes | Chief Financial Officer | Aug. 6, 2026 A | 700 | 1 | 0 | $11,200 |
| Vincent Paul Liptak | General Counsel | Aug. 10, 2026 C | 22,687 | 2 | 0 | $74,700 |
| Yishan Li | Executive Chairman | Aug. 10, 2026 C | 124,779 | 0 | 0 | $0 |
| Geoffrey Raymond Oxnard | Chief Medical Officer | Aug. 6, 2026 A | · | 0 | 0 | $0 |
| Sundeep Agrawal | Director | Aug. 10, 2026 C | 578,524 | 0 | 0 | $0 |
| John P. Schmid | Director | Aug. 10, 2026 P | 6,000 | 1 | 0 | $96,000 |
| GORDON CARL L | · | Aug. 10, 2026 C | 2,714,279 | 1 | 0 | $10,000,000 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
BLSM Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
5 analysts · 2026-09-30Mean target $35.40 +79.8%
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.